Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) Income from Continuing Operations: 2009-2025

Historic Income from Continuing Operations for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to -$1.1 million.

  • Lifecore Biomedical's Income from Continuing Operations rose 83.81% to -$1.1 million in Q2 2025 from the same period last year, while for May 2025 it was -$38.7 million, marking a year-over-year decrease of 514.93%. This contributed to the annual value of -$38.7 million for FY2025, which is 514.93% down from last year.
  • Lifecore Biomedical's Income from Continuing Operations amounted to -$1.1 million in Q2 2025, which was up 92.23% from -$14.8 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Income from Continuing Operations registered a high of $14.8 million during Q1 2024, and its lowest value of -$37.0 million during Q2 2023.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$9.2 million (2023), whereas its average is -$7.8 million.
  • Within the past 5 years, the most significant YoY rise in Lifecore Biomedical's Income from Continuing Operations was 254.79% (2023), while the steepest drop was 917.55% (2023).
  • Lifecore Biomedical's Income from Continuing Operations (Quarterly) stood at $7.5 million in 2021, then tumbled by 221.92% to -$9.2 million in 2022, then skyrocketed by 254.79% to $14.2 million in 2023, then plummeted by 146.14% to -$6.6 million in 2024, then soared by 83.81% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q2 2025, -$14.8 million for Q1 2025, and -$6.6 million during Q4 2024.